MedTrace Logo

AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

NCT01001091 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 312

Last updated 2014-07-17

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

AL-38583 ophthalmic solution

DRUG

AL-38583 ophthalmic solution vehicle

Inactive ingredients used as a placebo comparator

DRUG

Dexamethasone ophthalmic suspension, 0.1%

Sponsors & Collaborators

  • Ophthalmic Research Associates, Inc.

    collaborator INDUSTRY

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Michela Palmer · Alcon Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-04-30
Completion
2010-04-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01001091 on ClinicalTrials.gov